All In Biotech

NDA 020314 · Curium

Octreoscan

Indium In-111 Pentetreotide Kit · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Jun 2, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

128

87 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 21, 2022.

INDICATIONS AND USAGE Octreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 2, 1994 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • OCTREOSCAN · INDIUM IN-111 PENTETREOTIDE KIT 3mCi/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Indium In-111 Pentetreotide Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • intentional drug misuse31
  • death21
  • haemoglobin abnormal16
  • nausea15
  • drug ineffective14
  • platelet disorder10
  • product use issue10
  • disease progression8
  • product use in unapproved indication8
  • blood bilirubin abnormal7
  • haematotoxicity7
  • pyrexia7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20085
200917
201037
20113
20124
20145
20156
20165
20175
20188
20191
202021
20212
20222
20232
20244

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: Curium

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.